Evidence map›Paper›PMID 40825118›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Systemic

Elena Zamorano-Dominguez, Lucía Morales-Cacho, Rebeca Barrero, Silvia Jiménez-Parrado, Alma Dhawahir, Isabel Hernández-Porras, Lucía Simón-Carrasco, Sara Barrambana, Pian Sun, Ana Galván-Del-Rey and 10 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Elena Zamorano-Dominguez *Experimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Lucía Morales-Cacho *Experimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Rebeca BarreroExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Silvia Jiménez-ParradoExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Alma DhawahirGlobal Pharma Strategy, F. Hoffmann-La Roche Ltd, Basil 4070, Switzerland.
Isabel Hernández-PorrasExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Lucía Simón-CarrascoMolecular Oncology and Targeted Therapies Group, Centro Andaluz de Biología Molecular y Medicina Regenerativa, Consejo Superior de Investigaciones Científicas-Universidad de Sevilla-Universidad Pablo de Olavide, Seville 41092, Spain.
Sara BarrambanaExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Pian SunExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Ana Galván-Del-ReyExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Blanca Rosas-PerezExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Vasiliki LiakiExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Matthias DrostenCentro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid 28029, Spain.
Mónica MusteanuCentro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid 28029, Spain.
Federico VirgaExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Eugenio SantosCentro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid 28029, Spain.ORCID 0000-0003-3565-0321
Francisca MuleroMolecular Imaging Unit, Biotechnology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
Eduardo CaleirasHistopathology Unit, Biotechnology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.ORCID 0000-0001-8768-3630
Carmen GuerraExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.ORCID 0000-0002-3891-046X
Mariano BarbacidExperimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.ORCID 0000-0002-1480-2624

Funding

AECC fellowship PRDMA246123GALVCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB21/12/00121CRIS Cancer Fundation PID2021-124106OB-I00INPhINIT fellowship from the "la Caixa" Foundation LCF/BQ/DI18/11660011Juan de la Cierva felloship JDC2022-048924-IPortuguese Foundation for Science and Technology 2021.05875.BDSpanish Ministry of Science and Innovation FPU17/05962Spanish Ministry of Science and Innovation PRE2022-102952
6 · The paper itself

Abstract

The

Indexed as

HomeostasisMyeloid CellsProto-Oncogene Proteins p21(ras)AnimalsMiceMice, Inbred C57BLHras protein, mouseProto-Oncogene Proteins p21(ras)Hras and NrasKrasmyelomonocytic metaplasiapanRAS inhibitorssystemic ablation

Identifiers

PMID40825118
PMCPMC12403124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.